ArticleKidney medicine2025
Effectiveness of Allopurinol on Uric Acid and Pediatric Chronic Kidney Disease Severity in the Chronic Kidney Disease in Children Study.
Article in Kidney medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00327860 (Chronic Kidney Disease in Children Prospective Cohort Study), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Chronic Kidney Disease in Children Prospective Cohort Study (CKiD)
Who cites it
1 citing paper in PubMed.
- Pediatric hyperuricemia: genetic basis, metabolic mechanisms, and clinical implications.Frontiers in endocrinology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Rationale & Objective: Clinical trials have shown that serum uric acid reduction does not slow chronic kidney disease (CKD) progression in adults, but it is uncertain whether these findings apply to children. Study Design: An observational cohort study. Setting & Population: The Chronic Kidney Disease in Children cohort with participants who initiated allopurinol with a comparison group matched on age, sex, uric acid, CKD diagnosis, estimated glomerular filtration rate (eGFR), and proteinuria. Exposure: Allopurinol initiation. Outcomes: Uric acid, eGFR, and proteinuria before and after initiation, and longitudinal changes over time. Analytical Approach: Allopurinol initiators were matched to noninitiators at a 1:3 ratio. Nonparametric tests compared levels before and after initiation and within-person changes. Linear mixed effects models characterized baseline and longitudinal differences between treatment groups. Results: A total of 27 participants initiated allopurinol, and these were matched to 81 participants who did not initiate allopurinol. Allopurinol was associated with a 15.9% lower serum uric acid (95% CI, -21.1% to -10.4%) relative to the matched comparison group ( Limitations: Observational study designed for comparative effectiveness and relatively small sample size; effectiveness of allopurinol initiated at lower levels of uric acid could not be estimated. Conclusions: Allopurinol was effective at significantly lowering serum uric acid in children with CKD but was not associated with CKD progression measured by longitudinal eGFR and proteinuria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.